SleepSMART is a phase 3 multicenter, prospective randomized open-, blinded-endpoint controlled trial to test whether treatment of obstructive sleep apnea with positive airway pressure starting shortly after acute ischemic stroke and high-risk Transient Ischemic Attack (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality at 6 months, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke.
PRINCIPAL INVESTIGATOR: Sara Rostanski, MD
RESEARCH COORDINATOR: Lara Balick, MPH
ClinicalTrials.gov Identifier: NCT03812653
Supported by: National Institute of Neurological Disorders and Stroke (NINDS)
Status: Completed
Clarity is a Phase 3, randomized, double-blind, placebo-controlled, clinical trial of cilostazol in addition to anti-platelet treatment in patients with a history of a non-cardioembolic ischemic stroke or high-risk Transient Ischemic Attack. Participants will be followed for a maximum of 5 years for the primary outcome of a major adverse cardiovascular event (MACE).
PRINCIPAL INVESTIGATOR: Michela Rosso, MD
RESEARCH COORDINATOR: Lara Balick, MPH
ClinicalTrials.gov Identifier: NCT07174414
Supported by: National Institute of Neurological Disorders and Stroke (NINDS)
Status: Not yet recruiting
Bellevue Hospital Comprehensive Stroke Center Prospective Intracranial Atherosclerotic Disease (ICAD) Stroke Registry
BELLEVUE ICAD REGISTRY
This is a prospective research registry of patients with intracranial atherosclerotic disease (ICAD) undergoing treatment for ICAD at the Bellevue Comprehensive Stroke Center between April 2024 and April 2034. The objective of this registry is to create a resource of clinical and demographic data collected to better understand population health patterns and areas in need of health interventions.
PRINCIPAL INVESTIGATOR: Sara Rostanski, MD
RESEARCH COORDINATOR: Lara Balick, MPH
STUDY NUMBER: i24-00365
Status: Recruiting